Hyperfine (HYPR, Financial) has announced that it has received FDA clearance for its latest software innovation. This marks the tenth iteration of their technology, showcasing a significant enhancement in the quality of images produced through ultra-low-field MRI systems.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Hyperfine Inc (HYPR, Financial) is $0.98 with a high estimate of $1.50 and a low estimate of $0.68. The average target implies an upside of 48.86% from the current price of $0.66. More detailed estimate data can be found on the Hyperfine Inc (HYPR) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Hyperfine Inc's (HYPR, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Hyperfine Inc (HYPR, Financial) in one year is $1.86, suggesting a upside of 181.82% from the current price of $0.66. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Hyperfine Inc (HYPR) Summary page.
HYPR Key Business Developments
Release Date: May 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Hyperfine Inc (HYPR, Financial) delivered revenue of EUR2.1 million in Q1 2025 with the sale of six systems at a strong average selling price.
- The company successfully raised EUR6 million through a registered direct offering, extending its cash runway to the end of 2026.
- Hyperfine Inc (HYPR) is diversifying its revenue streams across hospitals, office settings, and international markets, which is expected to reduce variability and drive growth.
- The company is making progress in its office business, with pilot accounts now IAC accredited and actively scanning, and the Neurop PMR study progressing well.
- Hyperfine Inc (HYPR) anticipates regulatory approval and market entry in India in the second half of 2025, expanding its international presence.
Negative Points
- The company faced headwinds in Q1 2025 due to the loss of several deals at large academic institutions caused by reductions and cancellations of grant funding.
- US hospital sales cycles are experiencing longer deal timing and variability, impacting revenue predictability.
- Hyperfine Inc (HYPR) reported a net loss of $9.4 million for Q1 2025, equating to a net loss of $0.12 per share.
- The company experienced a significant cash burn in Q1 2025, with net cash burn excluding financing at $10.1 million.
- Hyperfine Inc (HYPR) adjusted its revenue guidance for the first half of 2025 to $5 to $6 million due to lost US deals from grant funding cancellations.
